MedTrace Logo

Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke

NCT05836740 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1724

Last updated 2025-05-14

No results posted yet for this study

Summary

The aim of this study was to evaluate the efficacy and safety of Minocycline versus placebo in the treatment of patients with moderate to severe acute ischemic stroke.

Conditions

  • Ischemic Stroke, Acute

Interventions

DRUG

Minocycline hydrochloride capsule

50 mg per capsule, containing 50mg of Minocycline Hydrochloride.

DRUG

Placebo capsules of Minocycline hydrochloride capsules

50 mg per capsule, containing 0mg of Minocycline Hydrochloride.

Sponsors & Collaborators

  • Neurodawn Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yilong Wang, PhD+MD · Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-19
Primary Completion
2024-05-20
Completion
2024-08-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05836740 on ClinicalTrials.gov